
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934.

Date of Report: October 18, 2013
(Date of earliest event reported)

Oragenics, Inc.
(Exact name of registrant as specified in its charter)

FL
(State or other jurisdiction
of incorporation)

001-32188
(Commission
File Number)

59-3410522
(IRS Employer
Identification Number)

4902 Eisenhower Boulevard, Suite 125
Tampa, FL
(Address of principal executive offices)

33634
(Zip Code)

813-286-7900
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01 Regulation FD Disclosure.

On October 18, 2013, the slide presentation (the "Presentation") of Oragenics, Inc. (the "Company") attached to this report as Exhibit 99.1 and incorporated herein by reference was posted in the Investors section of the Company's website www.oragenics.com. The Presentation is also expected to be used in connection with presentations to potential investors regarding any potential offering made pursuant to the Company's existing effective shelf registration statement, previously filed with the Securities and Exchange Commission. In addition, the Company may rely on all or part of this Presentation any time it is discussing the current state of the Company in communications with industry analysts, at conferences or with other investors in the Company's securities. This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state. Any offering of securities pursuant to the existing effective shelf registration statement will be made only by means of a prospectus and related prospectus supplement, when available.

The information set forth in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. In addition, the Presentation contains statements intended as "forward-looking statements" that are subject to the cautionary statements about forward-looking statements set forth in the Presentation.

By filing this Current Report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report. The information contained in this report is intended to be considered in the context of the Company's filings with the Securities and Exchange Commission ("SEC") and other public announcements that Oragenics makes, by press release or otherwise, from time to time. Oragenics undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any information contained in the Presentation should be read in the context of and with due regard to the more detailed information provided in other documents we file with or furnish to the SEC, including, but not limited to, our annual report on Form 10-K for the year ended December 31, 2012 and our quarterly report on Form 10-Q for the quarter ended June 30, 2013 and through press releases or through other public disclosure.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

<u>No.</u>	<u>Description</u>
99.1	Slide Presentation dated October 18, 2013.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 18th day of October, 2013.

ORAGENICS, INC.
(Registrant)

BY: /s/ John N. Bonfiglio

John N. Bonfiglio

Chief Executive Officer



Engineering New
Antibiotics and
Probiotics Through
Synthetic Biology

Investor Presentation


October 2013

Certain statements made in this presentation include forward-looking actions that Oragenics, Inc. (“Oragenics,” or the “Company”) anticipates based on certain assumptions. These statements are indicated by words such as “expect,” “anticipate,” “should” and similar words indicating uncertainty in facts, figures and outcomes. Such statements are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. While Oragenics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such statements will prove to be correct. The risks associated with the Company are detailed in the Company’s various reports filed by the Company with the Securities and Exchange Commission.

- ❑ **Oragenics Inc. (NYSEMKT: OGEN, market cap \$83M¹)** is focused on leveraging its expertise in antibiotics and probiotics with Intrexon's leading synthetic biology platform via two exclusive channel collaborations (ECCs) to develop novel biotherapeutics, including:
 1. **Lantibiotics:** a novel class of peptide antibacterial compounds produced by certain bacteria that display broad-spectrum activity against antibiotic-resistant strains such as Methicillin-resistant *Staphylococcus aureus* (MRSA), Vancomycin-resistant *Enterococcus* (VRE), *Clostridium difficile* (*C. diff*), Resistant Tuberculosis and other Gram-positive bacteria
 2. **Next Generation Probiotics:** bacteria-based biotherapeutics for oral cavity, throat, sinus, and esophagus diseases, beginning with Behçet's disease and aphthous stomatitis
- ❑ Oragenics also markets proprietary OTC oral care probiotics (ProBiora[®])

¹exclusive of shares from the second Intrexon ECC announced October 1, 2013

A Platform for Rapidly Engineering Bacterial Systems



Serious Need for New Antibiotics

“We Will Soon Be in a Post-Antibiotic Era”

The Sep. 2013 CDC report making headlines highlighted the serious threats of antibiotic-resistant infections and the need for new antibiotics:



- Over 2 million infections and 23,000 deaths each year in the U.S. are caused by resistant microbes
- Over \$20 billion in direct healthcare spending as a result of resistance infections
- Over \$35 billion in additional costs due to lost productivity



“Antibiotic Resistance Threats in the United States, 2013” U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Trends Support CDC Concerns

Resistance Increases While Approvals Decrease



Lantibiotics

A Promising Solution to the Growing Health Crisis of Antibacterial Resistance




Engineering New
Antibiotics and
Probiotics Through
Synthetic Biology

- Lantibiotics are a novel class of peptide antibacterial compounds:
 - Naturally-produced by a variety of Gram-positive bacterial strains to attack competing bacterial strains
 - There are more than 50 known lantibiotics, potentially creating a pipeline of new compounds to target resistant infections
 - Historically, their development as commercially-viable products has been limited by technological hurdles

- Oragenics is well-positioned to bring lantibiotics to the market:
 - Collaboration with Intrexon, a leader in synthetic biology, expected to enable the production of lantibiotics at commercial scale
 - Collaboration has already:
 - ✓ Produced a significant increase in production titer yield
 - ✓ Enabled development of robust purification methods compared to traditional approaches

Lead Lantibiotic Compound MU1140




- Initial focus is on MU1140, a lantibiotic shown to be effective against:
 - Methicillin-resistant *Staphylococcus aureus* (MRSA)
 - Vancomycin-resistant *Enterococcus* (VRE)
 - *Clostridium difficile* (*C. diff*)
 - Resistant Tuberculosis
 - Other Gram positive bacteria
- Preliminary preclinical data suggests:
 - Excellent therapeutic index
 - Minimal cytotoxicity in vitro using mouse and human cell lines; minimal immunogenicity
 - Maximum tolerated dose in mice and rats >50 mg/Kg
 - Plasma concentration-time profile declined bi-exponentially with a half life \cong 1.7 hr
 - In vivo efficacy observed in a pilot rat peritonitis model using *S. aureus* (60xLD₅₀)
 - Synergy with aminoglycosides

Plan for MU1140

First of 50+ Known Lantibiotics


- Intrexon collaboration has already produced a significant increase in fermentation titer and is developing a promising new purification process
- Matrix of early experiments planned to screen MU1140 (and several analogs/homologs) for determining primary efficacy (e.g. MICs, MTD, primary efficacy in animals, protein binding, etc.)
- Fermentation optimization/scale-up purification in progress
- IND filing expected by mid-2015*



* Current estimate may change depending on FDA pre-IND meeting results


- Synthetic biology is the application of engineering principles to the design of living organisms and their constituent parts (DNA, proteins, and cells)
- We are collaborating with Intrexon, a leading synthetic biology company, for the development and commercialization of lantibiotics for the treatment of infectious diseases in humans and companion animals
- Intrexon's toolset of modular molecular and cellular parts is expected to enable the engineering of specific functionality into cells to allow industrial scale production of lantibiotics

With Intrexon Collaboration Lantibiotics –For Resistant Bacterial Infections



Rising Market Demand for Novel Antibiotic Platforms

Significant valuations for “Single Antibiotic Product” companies – Orogenics has potential to generate a pipeline of antibiotics



Next Generation Probiotics

Potential to Revolutionize Probiotics for Oral Diseases



Engineering New
Antibiotics and
Probiotics Through
Synthetic Biology

- ▣ We are also developing, in collaboration with Intrexon, novel probiotics focusing on the treatment of patients with oral cavity, throat, sinus, and esophageal diseases
- ▣ Initial indications:
 - Behçet's disease -a chronic relapsing multi-systemic inflammatory disorder
 - Recurrent aphthous stomatitis (aka canker sores) –painful ulcers; the most common oral mucosal disease known
- ▣ As with lantibiotics, we expect to genetically manipulate bacteria; in this case beneficial bacteria that are naturally part of the human oral cavity microbiome
- ▣ The collaboration will focus on genetically-engineered bacterial strains designed to deliver and release therapeutics locally at the site of disease to target pain management, reduce inflammation, and improve patient outcomes

Lead Probiotic Programs


Behçet's Disease and Aphthous Stomatitis

- ▣ Behçet's disease - a chronic relapsing multi-systemic inflammatory disorder characterized by four major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions)
 - ▣ Patients suffering from Behçet's disease are often in constant pain and have difficulty eating
 - ▣ ~20,000 patients in the U.S.; similar for Europe
- ▣ Recurrent aphthous stomatitis (aka canker sores) –painful ulcers; the most common oral mucosal disease known
 - ▣ There are currently no effective treatments for aphthous stomatitis
 - ▣ ~200,000 patients in the U.S.

Oragenics/Intrexon Solution GM Probiotics For Oral Health



Choose the appropriate bacterial strain to engineer...



...insert genes responsible for production of therapeutics agent(s)...



...and deliver new therapeutic bacteria into the oral cavity to produce therapeutic benefits and supplement the natural oral microbiome.

ProBiora3[®] - OTC Product

First and Only Patented Probiotic Technology for Oral Care



Engineering New
Antibiotics and
Probiotics Through
Synthetic Biology

- Blend of 3 naturally-occurring, non-pathogenic bacteria – *S.oralis*, *S.uberis*, and *S.rattus* – is available without prescription and taken daily
- “Good” probiotic bacteria in ProBiora3[®] compete for binding sites and nutrients with “harmful” bacteria
- ProBiora3[®] bacteria also release hydrogen peroxide to reduce population of pathogens in mouth
- Poor oral health linked to serious health problems, including heart disease and diabetes; Total consumer oral care market expected to reach \$10.9 billion by 2014¹
- Also marketed for companion animals

¹*The US Market for Oral Care Products (2009)*, published by Packaged Facts

Novel Antibiotics (Lantibiotics)

- ▣ Significantly increased yield of MU1140 making commercialization a realistic goal
- ▣ Identified two new potentially viable purification methods for commercially producing MU1140
- ▣ Progress toward a genetically modified bacteria capable of higher yields of MU1140 and potentially analogs

Next Generation Probiotics

- ▣ Completed ECC with Intrexon – announced October 1, 2013
- ▣ Intrexon purchased \$3.9M of OGEN shares, with net proceeds to support initial efforts in this new area

Novel Antibiotics (Lantibiotics)

- ▣ Production of new lantibiotic analogs using genetically - modified bacteria – 1H '14
- ▣ Animal study results on MU1140/analog – 2H '13
- ▣ Announcement of results from pre-IND meeting with FDA- Mid '14

Next Generation Probiotics (Preliminary Timelines)

- ▣ Generation of next bacterial prototypes – 2H '14
- ▣ GMprobiotics producing cytokine therapeutics – Mid '15
- ▣ Proof-of-concept of a GMprobiotic to be used for therapeutic purposes in animals – 2H '15

OTC Probiotics

- ▣ Results from Indiana University clinical trial announced – 1H '14
- ▣ Publication of clinical study in children – 1H '14

Experienced Management Team

John N. Bonfiglio, Ph.D., President, CEO & Director

- ▣ 30 years of management and pharmaceutical experience
- ▣ Prior CEO Argos Therapeutics, CEO Immune Response, CEO PeregrinePharmaceuticals, COO Cypress Bio
- ▣ Senior Management positions at Allergan Pharmaceuticals and Baxter Healthcare
- ▣ MS and PhD in Chemistry, University of California, MBA Pepperdine University

Mike Sullivan, CFO

- ▣ Has held Senior-level financial positions for both publicly and privately held businesses
- ▣ Significant experience in product licensing and IP issues
- ▣ Strong background in both domestic and international retail operations
- ▣ Florida Certified Public Accountant, ex Big 4. MBA from The Florida State University

Dr. Martin Handfield, VP of Research & Development

- ▣ Former Tenured Associate Professor, College of Dentistry at The University of Florida
- ▣ Over 14 years experience with Oragenics
- ▣ Expert in biomarkers and research surrounding antimicrobials
- ▣ Over 40 publications and 6 patents

- NYSEMKT: OGEN
- Shareprice (as of 10/9/13) : \$3.00
- Market cap (as of 10/9/13) : \$83M*
- Sharesoutstanding (as of 6/30/13) : 27.5M*
- Cash(as of 6/30/13) : \$6.4M*
- Debt (as of 6/30/13) : \$142,000*
- Warrants and Options (as of 6/30/13) : 2.7M warrants and 670,000 options outstanding

*exclusive of shares, cash and promissory note from the second Intrexon ECC announced October 1, 2013